Cochrane

Review question For the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL) two different international standards are commonly used, either chemotherapy with escalated (intensified) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) regimen or chemotherapy with ABVD (doxorubicin, ...

Background Hodgkin lymphoma (HL) is a malignancy of the lymphatic system. It occurs in children and adults, but it is more common in the third decade of life. It is one of the most curable forms of cancer. There are four stages of HL, stages I and II are considered as early stage HL and stages III and IV as advanced stage. Using risk factors such ...

Review question To determine the benefit and harm of a restrictive red blood cell transfusion strategy when compared with a liberal red blood cell transfusion strategy for people diagnosed with a blood cancer (for example leukaemia, lymphoma, myeloma) who were receiving intensive treatments for their disease (chemotherapy or stem cell transplantation). Background People ...

Review question What is the best way to prevent bleeding for people being treated with intensive chemotherapy or stem cell transplantation for blood, or bone marrow cancers? Should we use platelet transfusions (the current standard treatment), or use other agents instead of (or as well as) platelet transfusions. Background Approximately one in eight ...

Background Multiple myeloma is a type of blood cancer, affecting plasma cells inside the bone marrow. Bortezomib is a type of treatment for myeloma called a proteasome inhibitor. Proteasomes are enzymes found in all cells and play an important role in cell function and growth. Cancer cells are more sensitive to the effects of bortezomib, causing cancer ...

In this systematic review, we summarised and analysed the evidence from randomised controlled trials on the efficacy and safety of granulocyte colony stimulating factors (G-CSF) and granulocyte-macrophage colony stimulating factors (GM-CSF) in the treatment of myelodysplastic syndromes (MDS). We searched several important medical databases and found ...

Review question: Is iron alone or iron as a supplement to erythropoiesis-stimulating agents (ESAs) superior to ESAs alone in the management of people diagnosed with chemotherapy-induced anemia (CIA)? Background: The current treatment of CIA is ESAs, which increase the production of red blood cells (erythropoiesis), and in some cases ESAs and iron. ...

Background Cancers of the bone marrow, lymphatic tissue and blood are considered as haematological malignancies. The most common types of haematological malignancies are lymphoma, leukaemia and myeloma but they also include myelodysplastic syndromes or myeloproliferative diseases. Within each type of disease there are various sub-divisions. There ...

Review question The objective of this review was to assess the efficacy of the treatment of lymphoma in children with antibody therapy in terms of survival, relapse rates and response to treatment, compared with therapy not including antibody treatment. Furthermore, it aimed to evaluate the effects of antibody therapy on quality of life and side effects. Background Lymphomas ...

Review question We reviewed the existing literature examining the efficacy and safety of granulocyte (macrophage) colony-stimulating factors (G(M)-CSF) compared to antibiotics to prevent infections for cancer patients receiving chemotherapy. Background Cancer treatment with chemotherapy (anti-cancer drugs) disrupts the immune system and lowers white ...